{"organizations": [], "uuid": "84176b172c59480c5ceac0dc7d3b3f1f20290b32", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-accepts-for-review-sanofis-sup/brief-fda-accepts-for-review-sanofis-supplemental-biologics-license-application-idUSASC09XCF", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Accepts For Review Sanofi's Supplemental Biologics License Application", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-04-25T21:33:00.000+03:00", "replies_count": 0, "uuid": "84176b172c59480c5ceac0dc7d3b3f1f20290b32"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-accepts-for-review-sanofis-sup/brief-fda-accepts-for-review-sanofis-supplemental-biologics-license-application-idUSASC09XCF", "ord_in_thread": 0, "title": "BRIEF-FDA Accepts For Review Sanofi's Supplemental Biologics License Application", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "review sanofi", "sentiment": "negative"}, {"name": "apps newsletters reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - SANOFI SA:\n* FDA ACCEPTS FOR REVIEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR 0.5 ML DOSE OF FLUZONEÂ® QUADRIVALENT (INFLUENZA VACCINE) IN CHILDREN 6-35 MONTHS OF AGE\n* DETAILED RESULTS FROM PHASE IV, RANDOMIZED, OBSERVER-BLINDED, CONTROLLED, MULTICENTER STUDY TO BE PRESENTED LATER THIS YEAR\n* PER THE PRESCRIPTION DRUG USER FEE ACT, THE TARGET ACTION DATE IS JANUARY 28, 2019\n* IF APPROVED, PHYSICIANS WILL BE ABLE TO RESERVE VACCINE FOR YOUNG CHILDREN FOR 2019-2020 FLU SEASON Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T21:33:00.000+03:00", "crawled": "2018-04-25T16:45:21.078+03:00", "highlightTitle": ""}